Free tool
FAERS Monitor: Zetia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021445 or its brand name (Zetia, Ezetimibe). Reports on generic versions are filed under their own applications.
Reports
76,879
Serious
50,222
65% of reports
Hospitalization
22,578
Death reported
4,407
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue5,145
- myalgia4,604
- nausea4,572
- diarrhoea4,115
- drug ineffective3,829
- dizziness3,694
- dyspnoea3,566
- headache3,507
- arthralgia3,164
- asthenia3,019
- pain2,984
- fall2,509
- pain in extremity2,503
- off label use2,492
- vomiting2,470
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,321 |
| 2005 | 2,248 |
| 2006 | 1,524 |
| 2007 | 1,599 |
| 2008 | 1,797 |
| 2009 | 1,831 |
| 2010 | 2,315 |
| 2011 | 2,115 |
| 2012 | 2,269 |
| 2013 | 1,897 |
| 2014 | 2,064 |
| 2015 | 3,133 |
| 2016 | 3,057 |
| 2017 | 2,994 |
| 2018 | 3,683 |
| 2019 | 4,009 |
| 2020 | 4,037 |
| 2021 | 3,990 |
| 2022 | 4,656 |
| 2023 | 5,346 |
| 2024 | 6,185 |
| 2025 | 7,349 |
| 2026 | 6,459 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,977,280 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myalgiaSignal | 4,604 | 7.6 | 7.4 | 25,819 |
| pain in extremitySignal | 2,503 | 2.3 | 2.2 | 1,921 |
| astheniaSignal | 3,019 | 2.2 | 2.1 | 2,010 |
| arthralgiaSignal | 3,164 | 2.1 | 2.0 | 1,820 |
| fallSignal | 2,509 | 2.1 | 2.0 | 1,399 |
| dizzinessSignal | 3,694 | 2.0 | 2.0 | 1,973 |
| fatigue | 5,145 | 1.8 | 1.8 | 1,935 |
| diarrhoea | 4,115 | 1.7 | 1.7 | 1,352 |
| dyspnoea | 3,566 | 1.7 | 1.7 | 1,116 |
| nausea | 4,572 | 1.6 | 1.5 | 1,016 |
| headache | 3,507 | 1.5 | 1.5 | 666 |
| vomiting | 2,470 | 1.4 | 1.4 | 337 |
| pain | 2,984 | 1.3 | 1.3 | 251 |
| drug ineffective | 3,829 | 0.8 | 0.8 | 217 |
| off label use | 2,492 | 0.8 | 0.7 | 164 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.